Global Information
회사소개 | 문의 | 비교리스트

세계의 폐색전증 치료제 시장(2019-2023년)

Global Pulmonary Embolism Therapeutics Market 2019-2023

리서치사 TechNavio (Infiniti Research Ltd.)
발행일 2019년 05월 상품 코드 843040
페이지 정보 영문 119 Pages
가격
US $ 2,500 ₩ 3,017,000 PDF (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,621,000 PDF (5-user License) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,828,000 PDF (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 6,035,000 PDF (Global License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다. 또한 해당 라이선스는 보고서 컨텐츠의 15% 이내로 외부용 문서에 인용 게재가 허용됩니다(예:프레스릴리스, 마케팅 자료, 백서 등).


세계의 폐색전증 치료제 시장(2019-2023년) Global Pulmonary Embolism Therapeutics Market 2019-2023
발행일 : 2019년 05월 페이지 정보 : 영문 119 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 폐색전증 치료제 시장은 지금까지 비경구 투여형 항응고제인 헤파린이 지배적이었습니다. 경구 투여형 항응고제는 기존의 비경구형 의약품과 비교해 환자 모니터링을 거의 필요로 하지 않기 때문에 인기가 더욱 높아질 것으로 예측됩니다. 시장은 2023년까지 9%의 CAGR로 성장할 것으로 전망됩니다.

세계의 폐색전증 치료제(Pulmonary Embolism Therapeutics) 시장을 조사했으며, 시장 개요, 투여 경로·지역별 시장 규모 추정과 예측, 시장 성장 촉진요인 및 과제 분석, 시장 동향, 경쟁 상황, 주요 기업 개요 등의 정보를 제공합니다.

목차

제1장 주요 요약

제2장 보고서 범위

제3장 시장 상황

  • 시장 생태계
  • 시장 특징
  • 시장 세분화 분석

제4장 시장 규모

  • 시장 정의
  • 시장 규모
  • 시장 규모 예측

제5장 Five Forces 분석

  • 구매자의 협상력
  • 공급 기업의 협상력
  • 신규 참여업체의 위협
  • 대체품의 위협
  • 경쟁 기업간 경쟁 관계
  • 시장 현황

제6장 시장 세분화 : 투여 경로별

  • 시장 구분 : 투여 경로별
  • 시장 비교 : 투여 경로별
  • 경구 투여
  • 비경구 투여
  • 시장 기회 : 투여 경로별

제7장 고객 상황

제8장 지역 상황

  • 시장 구분 : 지역별
  • 시장 비교 : 지역별
  • 북미
  • 유럽
  • 아시아
  • 주요 국가
  • 시장 기회

제9장 의사결정 체계

제10장 성장 촉진요인과 과제

  • 시장 성장 촉진요인
  • 시장 과제

제11장 시장 동향

  • 항응고 해독제에 관한 연구 증가
  • 전략적 제휴
  • 재생요법에 관한 광범위한 연구

제12장 벤더 상황

  • 개요
  • 창조적 파괴 상황
  • 경쟁 시나리오

제13장 벤더 분석

  • 대상 벤더
  • 벤더 분류
  • 벤더의 시장 포지셔닝
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • Daiichi Sankyo Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.

제14장 부록

  • 조사 방법
  • 약어 리스트
  • 벤더의 시장 포지셔닝

제15장 TechNavio 소개

KSM 19.05.23

About this market

The increasing awareness programs and campaigns are expected to trigger the pulmonary embolism therapeutics market growth during the forecast period. The increasing awareness campaigns will improve the awareness of the severity of blood clots, resulting in various patients undergoing diagnosis and treatment on time. Such growing popularity will eventually boost the market growth in the forthcoming years. Technavio's analysts have predicted that the pulmonary embolism therapeutics market will register a CAGR of 9% by 2023.

Market Overview

Increasing oral anticoagulants

Traditionally, the global pulmonary embolism therapeutics market was dominated by Heparin, an anticoagulant drug, which is administered through parenteral route. The market also had various other anticoagulant drugs that were approved; however, most of these drugs were administered through invasive routes. These drugs require no or very less patient monitoring unlike their predecessors from the parenteral route. This will further aid to the popularity of oral anticoagulants.

Preference for alternative therapies

The increasing popularity and the advances in alternative treatment methods are expected to pose a major challenge to the growth of the global pulmonary embolism therapeutics market during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the pulmonary embolism therapeutics market during 2019-2023, view our report.

Competitive Landscape

The market appears to be highly concentrated and with the presence of a few market players. Several vendors in the market are also entering into strategic alliances to manufacture the drugs so that they could concentrate on their core competencies such as research. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY ROA

  • Market segmentation by RoA
  • Comparison by RoA
  • Oral - Market size and forecast 2018-2023
  • Parenteral - Market size and forecast 2018-2023
  • Market opportunity by RoA

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Increasing research on anticoagulant antidotes
  • Strategic alliances
  • Extensive research on regenerative therapies

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • Daiichi Sankyo Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: RoA - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by RoA
  • Exhibit 19: Oral - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Oral - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Parenteral - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Parenteral - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Market opportunity by RoA
  • Exhibit 24: Customer landscape
  • Exhibit 25: Market share by geography 2018-2023 (%)
  • Exhibit 26: Geographic comparison
  • Exhibit 27: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 28: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 29: Top 3 countries in North America
  • Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Top 3 countries in Europe
  • Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 35: Top 3 countries in Asia
  • Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Top 3 countries in ROW
  • Exhibit 39: Key leading countries
  • Exhibit 40: Market opportunity
  • Exhibit 41: Impact of drivers and challenges
  • Exhibit 42: Vendor landscape
  • Exhibit 43: Landscape disruption
  • Exhibit 44: Vendors covered
  • Exhibit 45: Vendor classification
  • Exhibit 46: Market positioning of vendors
  • Exhibit 47: Boehringer Ingelheim International GmbH - Vendor overview
  • Exhibit 48: Boehringer Ingelheim International GmbH - Business segments
  • Exhibit 49: Boehringer Ingelheim International GmbH - Organizational developments
  • Exhibit 50: Boehringer Ingelheim International GmbH - Geographic focus
  • Exhibit 51: Boehringer Ingelheim International GmbH - Segment focus
  • Exhibit 52: Boehringer Ingelheim International GmbH - Key offerings
  • Exhibit 53: Boehringer Ingelheim International GmbH - Key customers
  • Exhibit 54: Bristol-Myers Squibb Co. - Vendor overview
  • Exhibit 55: Bristol-Myers Squibb Co. - Business segments
  • Exhibit 56: Bristol-Myers Squibb Co. - Organizational developments
  • Exhibit 57: Bristol-Myers Squibb Co. - Geographic focus
  • Exhibit 58: Bristol-Myers Squibb Co. - Key offerings
  • Exhibit 59: Bristol-Myers Squibb Co. - Key customers
  • Exhibit 60: Daiichi Sankyo Co. Ltd. - Vendor overview
  • Exhibit 61: Daiichi Sankyo Co. Ltd. - Business segments
  • Exhibit 62: Daiichi Sankyo Co. Ltd. - Organizational developments
  • Exhibit 63: Daiichi Sankyo Co. Ltd. - Geographic focus
  • Exhibit 64: Daiichi Sankyo Co. Ltd. - Key offerings
  • Exhibit 65: Daiichi Sankyo Co. Ltd. - Key customers
  • Exhibit 66: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 67: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 68: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 69: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 70: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 71: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 72: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 73: Johnson & Johnson Services Inc. - Vendor overview
  • Exhibit 74: Johnson & Johnson Services Inc. - Business segments
  • Exhibit 75: Johnson & Johnson Services Inc. - Organizational developments
  • Exhibit 76: Johnson & Johnson Services Inc. - Geographic focus
  • Exhibit 77: Johnson & Johnson Services Inc. - Segment focus
  • Exhibit 78: Johnson & Johnson Services Inc. - Key offerings
  • Exhibit 79: Johnson & Johnson Services Inc. - Key customers
  • Exhibit 80: Validation techniques employed for market sizing
  • Exhibit 81: Definition of market positioning of vendors
Back to Top
전화 문의
F A Q